Non-Infectious Uveitis Clinical Trial
— MkIIOfficial title:
A Controlled, Multi-Center Study of the Utilization and Safety of the MkII Inserter and the Safety of the FAI Insert in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye.
Verified date | April 2020 |
Source | EyePoint |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.
Status | Completed |
Enrollment | 26 |
Est. completion date | August 17, 2017 |
Est. primary completion date | August 17, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or non-pregnant female at least 18 years of age at time of consent 2. At least one eye has a history of non-infectious uveitis affecting the posterior segment 3. Subject has ability to understand and sign the Informed Consent Form 4. Subject is willing and able to comply with study requirements Exclusion Criteria: 1. Allergy to fluocinolone acetonide or any component of the FAI insert 2. Ocular malignancy in either eye, including choroidal melanoma 3. Uveitis with infectious etiology 4. Current viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella 5. Current mycobacterial infections of the eye or fungal diseases of ocular structures 6. Subjects who yield, during screening, a confirmed positive test for human immune deficiency virus (HIV) or syphilis 7. Systemic infection within 30 days prior to study Day 1 8. Peripheral retinal detachment in area of insertion 9. Elevated intraocular pressure (IOP) > 21 mmHg, or chronic hypotony < 6 mmHg 10. Concurrent therapy at screening with IOP-lowering pharmacologic agent in the study eye 11. Current diagnosis of any form of glaucoma or ocular hypertension in study eye at Screening, unless study eye has been previously treated with an incisional surgery procedure that has resulted in stable IOP in the normal range (10-21 mmHg) 12. Known history of clinically significant IOP elevation in response to steroid treatment in either eye, unless study eye has been previously treated with an incisional surgery procedure that has resulted in stable IOP in the normal range (10-21 mmHg) 13. Ocular surgery or capsulotomy performed on the study eye within 30 days prior to study Day 1 14. Intravitreal treatment of study eye: with FAI insert within 36 months prior to study Day 1;with Retisert within 30 months prior to study Day 1; with Ozurdex within 90 days prior to study Day 1; or with Triesence or Trivaris within 30 days prior to study Day 1 15. Peri-ocular or subtenon steroid treatment of study eye within 30 days prior to study Day 1 16. Treatment with an investigational drug or device within 30 days prior to study Day 1, except the FAI insert within this protocol 17. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to study Day 1 until the Month 12 Visit 18. Any condition which, in the judgment of the Investigator, could make the subject inappropriate for entry into this study |
Country | Name | City | State |
---|---|---|---|
United States | Texas Retina Associates | Arlington | Texas |
United States | Cleveland Clinic Foundation Cole Eye Institute | Cleveland | Ohio |
United States | Retina Consultants of Southern Colorado, PC | Colorado Springs | Colorado |
United States | Duke Eye Center | Durham | North Carolina |
United States | Charleston Neuroscience Institute | Ladson | South Carolina |
United States | Massachusetts Eye Research and Surgery Institution / Ocular Immunology & Uveitis Foundation | Waltham | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
EyePoint |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Utilization of the Mk II Inserter From the Day of Treatment Through 7 Days Following Treatment. | The primary utilization endpoint was defined as the proportion of intravitreal insertion procedures that were assessed by the investigator as satisfactory. A satisfactory procedure was defined as one receiving a score from the Investigator as either Very Easy, Easy, or Routine. | Day 7 | |
Secondary | The Safety of the FAI Insert During 12 Months Following Treatment Reported as Percentages. | To assess the safety of the FAI insert during 12 months following treatment reported as percentages. | Month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05928754 -
Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS
|
N/A | |
Terminated |
NCT00646425 -
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis
|
Phase 2 | |
Terminated |
NCT00456482 -
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant
|
Phase 2/Phase 3 | |
Recruiting |
NCT00720928 -
Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease
|
Phase 4 | |
Completed |
NCT04018599 -
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
|
Phase 1 | |
Terminated |
NCT02951975 -
Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye
|
||
Active, not recruiting |
NCT03634475 -
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
|
Phase 1/Phase 2 | |
Completed |
NCT04207983 -
A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)
|
Phase 2 | |
Recruiting |
NCT02706704 -
Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
|
Phase 2 | |
Terminated |
NCT01032915 -
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
|
Phase 3 | |
Not yet recruiting |
NCT04105452 -
Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)
|
Phase 2 | |
Terminated |
NCT01090310 -
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
|
Phase 3 | |
Completed |
NCT01694186 -
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
|
Phase 3 | |
Completed |
NCT03308045 -
Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis
|
Phase 1/Phase 2 | |
Completed |
NCT00468871 -
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy
|
Phase 2/Phase 3 |